We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+15.95%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$41.9M
AUM Growth
-$4.22M
Cap. Flow
-$8.19M
Cap. Flow %
-19.56%
Top 10 Hldgs %
48.42%
Holding
52
New
2
Increased
17
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$2.92M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$2.69M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$920K
4
ADMS
Adamas Pharmaceuticals
ADMS
+$693K
5
FBIO icon
Fortress Biotech
FBIO
+$499K

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.52M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$5.37M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2.06M
4
BIIB icon
Biogen
BIIB
+$861K
5
AMGN icon
Amgen
AMGN
+$806K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNX
51
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-10,891
Closed -$88K
MDCO
52
DELISTED
Medicines Co
MDCO
– –
-7,000
Closed -$257K
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2018 Portfolio in Review

As of Q3 2018, Opus Point Partners Management held 52 positions worth $41.9M, down 9.2% from $46.1M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Opus Point Partners Management withdrew a net $8.19M in Q3 2018, closing 5 positions and reducing 26 holdings. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $5.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 72% a quarter earlier.

Against the trend, Opus Point Partners Management opened a new position in Achillion Pharmaceuticals worth $1.14M.

  • Opus Point Partners Management's largest Q3 2018 buy was Achillion Pharmaceuticals: 308,569 shares worth $1.14M.
  • Opus Point Partners Management added most to TESARO, Inc. in Q3 2018, an estimated $2.92M increase.
  • Opus Point Partners Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $861K.
  • Opus Point Partners Management fully exited State Street SPDR S&P Biotech ETF in Q3 2018, selling an estimated $5.52M.
  • Opus Point Partners Management's ten largest holdings make up 48% of its $41.9M portfolio in Q3 2018.
  • Opus Point Partners Management opened 2 new positions and closed 5 in Q3 2018.
  • Opus Point Partners Management's portfolio value fell 9.2% quarter-over-quarter to $41.9M.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.